Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin versus investigator's choice chemotherapy in relapsed or refractory CD22-positive acute lymphoblastic leukemia
NL-OMON57782Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) (2 arms), sponsored by Pfizer. Primary endpoint: Hematological remission. Started May 2014; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NL-OMON57782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57782.